| Literature DB >> 33187149 |
Benoît Béganton1,2, Etienne Coyaud3, Estelle M N Laurent3, Alain Mangé2, Julien Jacquemetton4, Muriel Le Romancer4, Brian Raught3, Jérôme Solassol1,2.
Abstract
RAS proteins (KRAS, NRAS and HRAS) are frequently activated in different cancer types (e.g., non-small cell lung cancer, colorectal cancer, melanoma and bladder cancer). For many years, their activities were considered redundant due to their high degree of sequence homology (80% identity) and their shared upstream and downstream protein partners. However, the high conservation of the Hyper-Variable-Region across mammalian species, the preferential activation of different RAS proteins in specific tumor types and the specific post-translational modifications and plasma membrane-localization of each paralog suggest they could ensure discrete functions. To gain insights into RAS proteins specificities, we explored their proximal protein-protein interaction landscapes using the proximity-dependent biotin identification technology (BioID) in Flp-In T-REx 293 cell lines stably transfected and inducibly expressing wild type KRAS4B, NRAS or HRAS. We identified more than 800 high-confidence proximal interactors, allowing us to propose an unprecedented comparative analysis of wild type RAS paralogs protein networks. These data bring novel information on poorly characterized RAS functions, e.g., its putative involvement in metabolic pathways, and on shared as well as paralog-specific protein networks that could partially explain the complexity of RAS functions. These networks of protein interactions open numerous avenues to better understand RAS paralogs biological activities.Entities:
Keywords: BioID; RAS paralogs; interactome; protein–protein interaction
Year: 2020 PMID: 33187149 PMCID: PMC7696408 DOI: 10.3390/cancers12113326
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1The RAS interactome by BioID. (A) The network of RAS protein–protein interactions includes shared and specific interactors (prey) for the three indicated RAS paralogs. The prey protein location is based on their total spectral count, using the edge-weighted spring-embedded layout algorithm (Cytoscape v3.2.1). (B) Venn diagram showing the number of identified shared and specific interactors for the three indicated RAS paralogs. FB, FlagBirA* dual tag.
Figure 2Comparison of the RAS networks identified with BioID and IP-MS. (A) Venn diagrams of the shared and specific interactors identified by IP-MS and BioID, as well as the overlap with RAS interactors referenced in the BioGRID, MINT and HPRD databases. The average spectral counts and SAINT scores of selected interactors are described using the indicated color codes. (B) Venn diagram of the putative RAS interactors identified by BioID and IP-MS, as well as those referenced in the BIND, BioGRID and HPRD databases. (C) (Top) Comparison of the top five Gene Ontology Biological Process terms of the putative RAS interactors identified by BioID and IP-MS; and (Bottom) comparison of the top five protein domains in the putative RAS interactors identified by BioID and IP-MS. FB, FlagBirA* dual tag.
Figure 3Cellular localization of the RAS proximal interactors identified by BioID: (left) cell mapping of each RAS interactor determined by Gene Ontology analysis focused on cellular components; and (right) associated p values calculated for each cellular components and RAS paralog. FB, FlagBirA* dual tag; NI, not identified.
Figure 4Specific pathways of the RAS proximal interactors: (A) The KEGG pathway analysis identified SNARE interaction in vesicular transport (hsa04130), tight junctions (hsa04530), oxidative phosphorylation (hsa00190) and cell adhesion molecules (hsa04514) as significant RAS proximal interactor pathways; and (B) the Reactome pathway analysis identified the close proximity of RAS paralogs with proteins involved in the following metabolism-related pathways: amino-acid (AA) transport across the plasma membrane (HSA-352230), regulation of insulin secretion (HSA-422356), respiratory electron transport (HSA-611105) and energy-dependent regulation of mTOR by LKB1-AMPK (HSA-380972). H, FB-HRAS proximal interactor; N, FB-NRAS proximal interactor; K, FB-KRAS proximal interactor; FB, FlagBirA* dual tag.
Figure 5Features of RAS paralog-proximal interactors. (A) Based on the spectral count ratio of each interactor, a protein was considered as specific to one RAS paralog when at least two-fold more prey peptides were measured for that bait, and statistically significant (p value < 0.05) as determined by student’s t-test. (B) Comparison of Gene Ontology (GO) Biological Process and Cellular Component, InterPro protein domain, and KEGG pathway term enrichment for the interactors specific to each RAS paralog. The blue rectangles highlight terms that depict the most important differences between the compared RAS paralogs. FB, FlagBirA* dual tag.
FB-HRAS and FB-NRAS specific functions. The significant FB-HRAS and FB-NRAS-specific functions were determined by Gene Ontology Biological Processes analysis (p value < 0.05).
| Bait Proteins | Gene Ontology Biological Processes | Count | Identified Proteins | |
|---|---|---|---|---|
|
| Protein transport (GO:0015031) | 44 | 1.47 × 10−6 | AHCYL1, ANXA2, BSG, BTN3A1, C14orf133, CHMP5-6, DYNLL1, GDI2, GIPC1, NAPA, NDUFAF2, NOP58, PSEN1, RAB11FIP2, RAB12/21/23, SCAMP1, SEC61A1, SLC9A3R1, SNX3/6/12/17, SRC, SRP9, STX3-4/6-7/12, STXBP1, TBC1D10A, TIMM13/23, TMED10, TOMM6, VAMP2/4/8, VPS33A, YKT6, YWHAH |
| Single-organism membrane fusion (GO:0060627) | 13 | 4.91 × 10−6 | ANXA2, STX12, STX3-4/6-7, STXBP1, TC2N, VAMP2/4/8, VAT1, YKT6 | |
| Regulation of vesicle-mediated transport (GO:0060627) | 19 | 2.40 × 10−5 | ANXA2, B2M, CHMP6, CNN2, NAPA, NCS1, RAB21, RDX, SNX3/6/12/17, SRC, STX4, TBC1D10A, TC2N, VAMP2/8 | |
| Endosomal transport (GO:0016197) | 14 | 6.98 × 10−5 | C14orf133, CHMP5-6, RAB12/21, RDX, SNX3/6/12/17, STX6, TBC1D10A, VPS33A, YKT6 | |
| Exocytosis (GO:0006887) | 17 | 1.00 × 10−4 | CHMP6, NAPA, NCS1, PSEN1, RAB11FIP2, SCAMP1, SNX6, STX3-4, STXBP1, TC2N, TMED10, VAMP2/4/8, VPS33A, YKT6 | |
|
| Transmembrane transport (GO:0055085) | 15 | 1.41 × 10−3 | AKT2, ANK3, CNKSR3, EBP, SLC2A1, SLC5A6, SLC16A10, SLC25A1, SLC30A5-6, SLC35A2/E1, UBB, ZDHHC13/17 |
FB, FlagBirA* dual tag.
FB-HRAS and FB-KRAS specific protein domains. The significant FB-HRAS and FB-KRAS-specific protein domains were determined by InterPro analysis (p value < 0.05).
| Bait Proteins | InterPro Protein Domains | Count | Identified Proteins | |
|---|---|---|---|---|
|
| Syntaxin/epimorphin, conserved site (IPR006012) | 5 | 2.07 × 10−3 | STX3-4/6-7/12 |
| t-SNARE (IPR010989) | 5 | 2.16 × 10−3 | STX3-4/6-7/12 | |
| Synaptobrevin (IPR001388) | 4 | 8.66 × 10-3 | VAMP2/4/8, YKT6 | |
|
| CRAL-TRIO domain (IPR001251) | 4 | 2.10 × 10−2 | NF1, MOSPD2, KALRN, TRIO |
FB, FlagBirA* dual tag.
Figure 6Validation by PLA of specific RAS paralogs interactors. (A) Detection by PLA of the interaction between the indicated FB-RAS paralogs and HA-BRAF (positive control). PLA was performed with anti-Flag and anti-HA antibodies. The detected pairs are represented by red dots. Nuclei were counterstained with DAPI (blue). Expression of HA-BRAF and the tetracycline-dependent expression of the FB-RAS paralogs were confirmed by Western blotting. The PLA negative control was performed using FB-RAS-induced cells transfected with the empty HA vector. (B) PLA detection of the specific FB-HRAS, FB-NRAS and FB-KRAS interaction with HA-tagged RAP2A, SHKBP1 and PGD, respectively. PLA was performed as in A and the ectopic expression of the HA-tagged interactors was validated by Western blotting (Figure S4). Quantification of the dots per cell was performed using ImageJ and the plugin “Counter cells”. Data are the mean ± SEM of 100 cells/condition. ***, p value ≤ 0.0001 (Student’s t-test). FB, FlagBirA* dual tag; Tet., tetracycline.